Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations Yahoo Finance senior health reporter Anjalee Khemlani joins the Catlaysts team to share the biggest takeaways from the pharmaceutical giant's earnings, including its global position in the GLP-1 weight-loss drug space and its partnership with CVS Health (CVS). Catch Anjalee Khemlani's full interview with Novo Nordisk CEO Lars Jørgensen. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. Video Transcript 00:00 Seana Smith Shares of drugmaker Novo Nordisk moving higher after beating Wall Street's profit estimates for the latest quarter. Here with the three biggest takeaways from Novo's earnings, we've got Yahoo! Finance senior reporter Anjalee Khemlani. Anjalee, it's great to have you. It's interesting to see the stock price moving up even though they did trim their outlook, but it seems that was already kind of priced in heading into the print. 00:18 Anjalee Khemlani Yeah, the company has been one of those that has been under pressure, we know, of course, because of competition heating up with competitor Eli Lilly, and Novo came out saying that they're looking forward to kind of recovering a little bit in the second quarter. So my biggest takeaways from the earnings and also from speaking with CEO Lars Jörgensen, was first of all, looking at that global dominance. So we have the perception of those prescriptions of Lilly's Zepound taking over, but he reminded us that the company does have 72% of global market share. So that's something to keep an eye on. In addition, taking a look at the at the sales for the second half of the year, those compounding products, that has been part of what has pressured the company sales, and they they're looking towards the relief with enforcement from the FDA towards the end of the month to take those compounded products off the market, and that would lead to, hopefully, a regaining of those sales. But they did still cut it down by about 3%, on both ends. So it was 16 to 24 previously, and now the outlook has softened a little bit. And then finally, taking a look at what we have going on with the company's CVS deal, that was a big thing for them, getting that exclusive deal with the formulary. Knocked Lily's stock down last week. But I heard from the CEO that that was actually not their idea. It was CVS pursuing that. They didn't have to do any price concessions, and that's something that they just kind of got as a gift. 02:07 Seana Smith Wow. I am fascinated by that, and eager to hear more about it in your interview with him. Anjalee, thank you so much. Really appreciate it. Related Videos 01:04 Alphabet reacts to Apple, Coupang buyback, Wynn Resorts upgrade Yahoo Finance Video • 40 minutes ago 01:06 Upstart outlook, Spotify playlists, Amazon invests $4B into Chile Yahoo Finance Video • 1 hour ago 40:45 Fed's rate lookahead, Novo Nordisk CEO, Trump tariffs: Catalysts Yahoo Finance Video • 2 hours ago 02:59 ETF flows surge as investors weigh managed risk vs. safety Yahoo Finance Video • 1 hour ago
3 major takeaways from Novo Nordisk's Q1 earnings
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...